Tag: non alcoholic steatohepatitis treatment market size

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Non-Alcoholic Steatohepatitis Treatment Market Valued at Present and by 2029?

The scale of the non-alcoholic steatohepatitis treatment market has surged rapidly in the past few years. This market is projected to expand from $2.6 billion in 2024 to $3.57 billion in 2025, indicating a compound annual growth rate (CAGR) of 37.5%. The boost in growth during the historical period can be credited to the increasing occurrence of NASH, growing recognition and diagnosis, alterations in lifestyle and the obesity crisis, clinical studies, access to healthcare infrastructure, regulatory backing and clinical trials.

The market size for treatment of non-alcoholic steatohepatitis is anticipated to witness a staggering growth in the coming years, elevating to “$13.57 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 39.6%. This expected surge during the forecast period can be connected to factors such as progress in drug formulation, heightened awareness of the disease, increased occurrence and risk factors, and a shift towards individualized healthcare. Significant trends anticipated during the forecast period encompass a patient-focused approach, technological progress, targeted treatment options, modifications in regulatory policies, and advancements in scientific research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

#What Drivers Are Influencing Growth In The Non-Alcoholic Steatohepatitis Treatment Market?

The surge in insulin resistance cases is influencing the non-alcoholic steatohepatitis treatment market’s expansion. Insulin resistance is a condition in which muscle, fat, and liver cells don’t respond effectively to insulin, making it difficult for them to absorb glucose from the bloodstream and resulting in elevated blood sugar levels. It’s often associated with an unhealthy lifestyle, high sugar intake, and genetic factors. The number of insulin resistance cases has soared owing to the upswing in diabetes and other liver-related problems, all of which are addressed with non-alcoholic steatohepatitis treatment. For example, a report by the International Diabetes Federation, a Belgium-based global diabetes community in January 2022, noted that diabetes afflicts 537 million people aged 20-79, accounting for one in ten individuals. This number is set to rise to 643 million by 2030 and 783 million by 2045. Besides, the American Cancer Society, a US nonprofit cancer advocacy organization, projected in January 2024 that new liver cancer incidents would be around 41,630 in 2024, slightly higher than the 41,210 cases in 2023. Consequently, the rising occurrence of insulin resistance, fueled by multiple liver diseases and diabetes, will bolster the non-alcoholic steatohepatitis treatment market.

What Are The Main Segments Identified In The Non-Alcoholic Steatohepatitis Treatment Market Research?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

What Trends Are Currently Influencing Growth In The Non-Alcoholic Steatohepatitis Treatment Market?

The growth in the non-alcoholic steatohepatitis (NASH) drug advancement has emerged as a pivotal trend in the NASH treatment market. Numerous firms are directing their investments towards creating novel drugs with fewer side effects to combat liver diseases. For instance, in May 2022, Pfizer Inc., the American pharmaceutical and biotech company, received approval from the U.S. Food and Drug Administration (FDA) under fast-track designation to foster the development of two NASH drugs, ervogastat and clesacostat. The fast-track process was established to accelerate the development of Pfizer’s experimental combination therapy known as ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi) for treating non-alcoholic steatohepatitis (NASH) with liver fibrosis.

Which Companies Play A Key Role In The Development Of The Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Are The Key Regional Developments Shaping The Non-Alcoholic Steatohepatitis Treatment Market?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Non-Alcoholic Steatohepatitis Treatment Market Grown from 2024 to 2025?

In the last few years, the market for non-alcoholic steatohepatitis treatment has witnessed a significant upsurge. Its expansion is set to continue, rising from $2.6 billion in 2024 to $3.6 billion in 2025 with a compound annual growth rate of 38.5%. Various factors have contributed to the growth observed in the historic period such as the increasing occurrence of NASH, enhanced awareness and diagnosis, lifestyle modifications and growing obesity crises, in-depth clinical research, improvements in healthcare infrastructure and accessibility, regulatory backing, and clinical trials.

What Growth Rate Is Anticipated for the Non-Alcoholic Steatohepatitis Treatment Market in the Coming Years?

The market for non-alcoholic steatohepatitis treatment is anticipated to witness a significant surge in the coming years, with its value projected to reach $13.83 billion by 2029, expanding at a compound annual growth rate (CAGR) of 40.0%. The expected growth during the forecast period can be credited to progress in drug discovery, heightened disease understanding, increasing incidence and risk factors, along with a shift towards personalized healthcare. Key trends predicted for the coming period include a more patient-focused approach, technological innovation, targeted treatments, evolving regulatory environment, and advances in research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Who Are the Leading Companies in the Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

What Are the Key Drivers of the Non-Alcoholic Steatohepatitis Treatment Market?

Insulin resistance’s growing prevalence has been a major contributor to the expansion of the non-alcoholic steatohepatitis treatment market. When insulin resistance happens, muscle, fat, and liver cells don’t respond properly to insulin, making glucose absorption from the blood difficult, which in turn leads to high blood sugar. This condition is often associated with an unhealthy lifestyle, overconsumption of sugar, and genetic factors. Insulin resistance has become more common due to the increase in diabetes and other liver-related conditions, which are managed by non-alcoholic steatohepatitis treatment. For example, as per the latest report from the International Diabetes Federation, a global diabetes community based in Belgium, in January 2022, 537 million individuals (20-79 years old) are currently affected by diabetes, representing one in ten individuals. This figure is predicted to rise to 643 million by 2030, and 783 million by 2045. Additionally, the American Cancer Society, a nonprofit cancer advocacy group in the US, anticipates new liver cancer cases in 2024 to be 41,630, up from 41,210 in 2023. Consequently, the growing prevalence of insulin resistance due to various liver and diabetes diseases is predicted to boost the non-alcoholic steatohepatitis treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

What Are the Key Market Segments in the Non-Alcoholic Steatohepatitis Treatment Industry?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

What Are the Latest Trends in the Non-Alcoholic Steatohepatitis Treatment Market?

The evolution of non-alcoholic steatohepatitis (NASH) medication is emerging as a significant trend in the non-alcoholic steatohepatitis therapy market. Numerous firms are directing their resources towards the invention of innovative drugs aimed at liver disease treatment, minimizing the side effects. For instance, Pfizer Inc., a leading American pharmaceutical and biotechnology corporation, was granted fast-track designation in May 2022 by the U.S. Food and Drug Administration (FDA) to expedite the development process of its NASH drug, specifically ervogastat and clesacostat. Fast Track is a designed program to expedite the development of Pfizer’s investigative combination therapy for non-alcoholic steatohepatitis (NASH) with liver fibrosis, namely ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Are the Key Regional Markets in the Non-Alcoholic Steatohepatitis Treatment Industry?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595

This Report Delivers Insight On:

1. How big is the non-alcoholic steatohepatitis treatment market, and how is it changing globally?

2. Who are the major companies in the non-alcoholic steatohepatitis treatment market, and how are they performing?

3. What are the key opportunities and risks in the non-alcoholic steatohepatitis treatment market right now?

4. Which products or customer segments are growing the most in the non-alcoholic steatohepatitis treatment market?

5. What factors are helping or slowing down the growth of the non-alcoholic steatohepatitis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Non-Alcoholic Steatohepatitis Treatment Market Grown from 2024 to 2025?

In the last few years, the market for non-alcoholic steatohepatitis treatment has witnessed a significant upsurge. Its expansion is set to continue, rising from $2.6 billion in 2024 to $3.6 billion in 2025 with a compound annual growth rate of 38.5%. Various factors have contributed to the growth observed in the historic period such as the increasing occurrence of NASH, enhanced awareness and diagnosis, lifestyle modifications and growing obesity crises, in-depth clinical research, improvements in healthcare infrastructure and accessibility, regulatory backing, and clinical trials.

What Growth Rate Is Anticipated for the Non-Alcoholic Steatohepatitis Treatment Market in the Coming Years?

The market for non-alcoholic steatohepatitis treatment is anticipated to witness a significant surge in the coming years, with its value projected to reach $13.83 billion by 2029, expanding at a compound annual growth rate (CAGR) of 40.0%. The expected growth during the forecast period can be credited to progress in drug discovery, heightened disease understanding, increasing incidence and risk factors, along with a shift towards personalized healthcare. Key trends predicted for the coming period include a more patient-focused approach, technological innovation, targeted treatments, evolving regulatory environment, and advances in research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Who Are the Leading Companies in the Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

What Are the Key Drivers of the Non-Alcoholic Steatohepatitis Treatment Market?

Insulin resistance’s growing prevalence has been a major contributor to the expansion of the non-alcoholic steatohepatitis treatment market. When insulin resistance happens, muscle, fat, and liver cells don’t respond properly to insulin, making glucose absorption from the blood difficult, which in turn leads to high blood sugar. This condition is often associated with an unhealthy lifestyle, overconsumption of sugar, and genetic factors. Insulin resistance has become more common due to the increase in diabetes and other liver-related conditions, which are managed by non-alcoholic steatohepatitis treatment. For example, as per the latest report from the International Diabetes Federation, a global diabetes community based in Belgium, in January 2022, 537 million individuals (20-79 years old) are currently affected by diabetes, representing one in ten individuals. This figure is predicted to rise to 643 million by 2030, and 783 million by 2045. Additionally, the American Cancer Society, a nonprofit cancer advocacy group in the US, anticipates new liver cancer cases in 2024 to be 41,630, up from 41,210 in 2023. Consequently, the growing prevalence of insulin resistance due to various liver and diabetes diseases is predicted to boost the non-alcoholic steatohepatitis treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

What Are the Key Market Segments in the Non-Alcoholic Steatohepatitis Treatment Industry?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

What Are the Latest Trends in the Non-Alcoholic Steatohepatitis Treatment Market?

The evolution of non-alcoholic steatohepatitis (NASH) medication is emerging as a significant trend in the non-alcoholic steatohepatitis therapy market. Numerous firms are directing their resources towards the invention of innovative drugs aimed at liver disease treatment, minimizing the side effects. For instance, Pfizer Inc., a leading American pharmaceutical and biotechnology corporation, was granted fast-track designation in May 2022 by the U.S. Food and Drug Administration (FDA) to expedite the development process of its NASH drug, specifically ervogastat and clesacostat. Fast Track is a designed program to expedite the development of Pfizer’s investigative combination therapy for non-alcoholic steatohepatitis (NASH) with liver fibrosis, namely ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Are the Key Regional Markets in the Non-Alcoholic Steatohepatitis Treatment Industry?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595

This Report Delivers Insight On:

1. How big is the non-alcoholic steatohepatitis treatment market, and how is it changing globally?

2. Who are the major companies in the non-alcoholic steatohepatitis treatment market, and how are they performing?

3. What are the key opportunities and risks in the non-alcoholic steatohepatitis treatment market right now?

4. Which products or customer segments are growing the most in the non-alcoholic steatohepatitis treatment market?

5. What factors are helping or slowing down the growth of the non-alcoholic steatohepatitis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Non-Alcoholic Steatohepatitis Treatment Market Grown from 2024 to 2025?

In the last few years, the market for non-alcoholic steatohepatitis treatment has witnessed a significant upsurge. Its expansion is set to continue, rising from $2.6 billion in 2024 to $3.6 billion in 2025 with a compound annual growth rate of 38.5%. Various factors have contributed to the growth observed in the historic period such as the increasing occurrence of NASH, enhanced awareness and diagnosis, lifestyle modifications and growing obesity crises, in-depth clinical research, improvements in healthcare infrastructure and accessibility, regulatory backing, and clinical trials.

What Growth Rate Is Anticipated for the Non-Alcoholic Steatohepatitis Treatment Market in the Coming Years?

The market for non-alcoholic steatohepatitis treatment is anticipated to witness a significant surge in the coming years, with its value projected to reach $13.83 billion by 2029, expanding at a compound annual growth rate (CAGR) of 40.0%. The expected growth during the forecast period can be credited to progress in drug discovery, heightened disease understanding, increasing incidence and risk factors, along with a shift towards personalized healthcare. Key trends predicted for the coming period include a more patient-focused approach, technological innovation, targeted treatments, evolving regulatory environment, and advances in research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Who Are the Leading Companies in the Non-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

What Are the Key Drivers of the Non-Alcoholic Steatohepatitis Treatment Market?

Insulin resistance’s growing prevalence has been a major contributor to the expansion of the non-alcoholic steatohepatitis treatment market. When insulin resistance happens, muscle, fat, and liver cells don’t respond properly to insulin, making glucose absorption from the blood difficult, which in turn leads to high blood sugar. This condition is often associated with an unhealthy lifestyle, overconsumption of sugar, and genetic factors. Insulin resistance has become more common due to the increase in diabetes and other liver-related conditions, which are managed by non-alcoholic steatohepatitis treatment. For example, as per the latest report from the International Diabetes Federation, a global diabetes community based in Belgium, in January 2022, 537 million individuals (20-79 years old) are currently affected by diabetes, representing one in ten individuals. This figure is predicted to rise to 643 million by 2030, and 783 million by 2045. Additionally, the American Cancer Society, a nonprofit cancer advocacy group in the US, anticipates new liver cancer cases in 2024 to be 41,630, up from 41,210 in 2023. Consequently, the growing prevalence of insulin resistance due to various liver and diabetes diseases is predicted to boost the non-alcoholic steatohepatitis treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smp

What Are the Key Market Segments in the Non-Alcoholic Steatohepatitis Treatment Industry?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

What Are the Latest Trends in the Non-Alcoholic Steatohepatitis Treatment Market?

The evolution of non-alcoholic steatohepatitis (NASH) medication is emerging as a significant trend in the non-alcoholic steatohepatitis therapy market. Numerous firms are directing their resources towards the invention of innovative drugs aimed at liver disease treatment, minimizing the side effects. For instance, Pfizer Inc., a leading American pharmaceutical and biotechnology corporation, was granted fast-track designation in May 2022 by the U.S. Food and Drug Administration (FDA) to expedite the development process of its NASH drug, specifically ervogastat and clesacostat. Fast Track is a designed program to expedite the development of Pfizer’s investigative combination therapy for non-alcoholic steatohepatitis (NASH) with liver fibrosis, namely ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Are the Key Regional Markets in the Non-Alcoholic Steatohepatitis Treatment Industry?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595

This Report Delivers Insight On:

1. How big is the non-alcoholic steatohepatitis treatment market, and how is it changing globally?

2. Who are the major companies in the non-alcoholic steatohepatitis treatment market, and how are they performing?

3. What are the key opportunities and risks in the non-alcoholic steatohepatitis treatment market right now?

4. Which products or customer segments are growing the most in the non-alcoholic steatohepatitis treatment market?

5. What factors are helping or slowing down the growth of the non-alcoholic steatohepatitis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theNon-Alcoholic Steatohepatitis Treatment Market?

The surge in insulin resistance, which is the condition when the body’s muscles, fat, and liver cells fail to adequately react to insulin, thereby leading to higher blood sugar levels, is a key driver in the rise of the non-alcoholic steatohepatitis treatment market. This condition is often related to unhealthy lifestyles, overconsumption of sugar, and genetic predispositions. The need for treating insulin resistance has amplified due to the surge in cases of diabetes and other liver-related disorders with non-alcoholic steatohepatitis treatments. As per data from the International Diabetes Federation based in Belgium, 537 million people aged 20 to 79, or one out of every ten, had diabetes in January 2022 and this number is projected to climb to 643 million by 2030 and 783 million by 2045. Similarly, new cases of liver cancer are forecasted to hit 41,630 in 2024, an increase from 41,210 in 2023, according to the US-based American Cancer Society in January 2024. Hence, the rising occurrence of insulin resistance caused by various liver ailments and diabetes is expected to bolster the non-alcoholic steatohepatitis treatment market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

How Will the Growth Rate of theNon-Alcoholic Steatohepatitis Treatment Market Impact Industry Trends by 2034?

The market size for non-alcoholic steatohepatitis treatment has seen steep growth in recent years. It is projected to expand from $2.6 billion in 2024 to $3.6 billion in 2025, with a compound annual growth rate (CAGR) of 38.5%. Elements contributing to the growth during the historical period include an increase in NASH cases, enhanced awareness and diagnosis, changes in lifestyle and an obesity crisis, advancements in clinical research, improvement in healthcare infrastructure and accessibility, supportive regulatory frameworks, and ongoing clinical trials.

Anticipated to experience significant expansion in the coming years, the market size for non-alcoholic steatohepatitis treatment is projected to surge to $13.83 billion by 2029, with a compound annual growth rate (CAGR) of 40.0%. The predicted growth during the forecast period is due to factors such as the progression in drug development, heightened disease consciousness, an increasing prevalence and risk factor, and a shift towards bespoke medicine. The forecast period is expected to showcase trends like a patient-focused approach, technological progress, targeted therapies, regulation changes, and research advancements.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595

Which Upcoming Market Trends and Innovations Are Set to Influence theNon-Alcoholic Steatohepatitis Treatment Market’s Path Forward?

The trend of developing drugs for non-alcoholic steatohepatitis (NASH) is gaining prominence in the NASH treatment market. Numerous firms are putting their resources towards the development of innovative medicines for liver ailments, with a reduced drug side effect profile. For example, in May 2022, Pfizer Inc., a prominent pharmaceutical and biotechnology corporation from the United States, was awarded a grant by the U.S. Food and Drug Administration (FDA) for a fast-track designation to expedite the development of their NASH drug, namely ervogastat and clesacostat. The Fast Track is a process specifically designed to speed up the development of Pfizer’s investigational combination therapy for treating NASH with liver fibrosis named as, ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).

Who Are the Dominant Market Players Pushing the Boundaries of theNon-Alcoholic Steatohepatitis Treatment Market?

Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Are the Core Segments of the Non-Alcoholic Steatohepatitis Treatment Market, and How Do They Contribute to Growth?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=8595&type=smpGlobal Non-Alcoholic Steatohepatitis Treatment Market, Global Non-Alcoholic Steatohepatitis Treatment Market Report, Global Non-Alcoholic Steatohepatitis Treatment Market Trends, Global Non-Alcoholic Steatohepatitis Treatment Market Size

Browse Through More Reports Similar to the Gobal Non-Alcoholic Steatohepatitis Treatment Maret 2025, By The Business Research Company:

Protein Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/protein-supplements-global-market-report

Nutritional Analysis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/nutritional-analysis-global-market-report

Probiotics Dietary Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/probiotics-dietary-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the Non-Alcoholic Steatohepatitis Treatment Market’s Growth Rate Evolve Over the Forecast Period to 2034?

The market for non-alcoholic steatohepatitis treatments has seen a significant rise in its size in the recent past. It is projected to expand from a value of $2.6 billion in 2024 to an impressive $3.6 billion in 2025, with a compound annual growth rate (CAGR) of 38.5%. The growth noted in the historical period can be identified to the increasing cases of NASH, improving awareness and diagnoses, changes in lifestyle and obesity outbreak, advancements in clinical research, access and improvements to healthcare infrastructure, regulatory backing, and clinical trial developments.

In the forthcoming years, the market size for non-alcoholic steatohepatitis treatment is forecasted to witness substantial growth, ballooning to $13.83 billion by 2029 with a compound annual growth rate (CAGR) of 40.0%. This upswing during the forecast period is tied to progress in drug innovation, heightened understanding of the disease, burgeoning prevalence and risk factor, coupled with a transition to personalized medicine. In the same timeline, key developments are set to be patient-centric methodologies, breakthroughs in technology, focused therapies, regulatory framework, and improvements in scientific research.

What Key Drivers Are Accelerating the Growth of the non-alcoholic steatohepatitis treatment Market During the Forecast Period?

The escalation in the occurrence of insulin resistance has become a driving force for the expansion of the non-alcoholic steatohepatitis treatment market. Insulin resistance transpires when the body’s muscles, fat, and liver cells fail to adequately respond to insulin, impeding the easy absorption of glucose from the bloodstream, hence instigating high blood sugar levels. Requirements for insulin resistance are tied to poor lifestyle habits, excessive intake of sugar, and inherited traits. The growing prevalence of diabetes and various liver-related health issues have amplified the demand for insulin resistance treatment, primarily managed by non-alcoholic steatohepatitis care. For example, a report in January 2022 by the International Diabetes Federation, a diabetes community based in Belgium, indicated that diabetes impacts 537 million individuals aged 20-79, equivalent to one in every ten people. This figure is projected to rise to 643 million by 2030 and 783 million by 2045. Additionally, a forecast in January 2024 by the American Cancer Society, a U.S. nonprofit cancer advocacy group, predicted that new liver cancer incidences would amount to 41,630 in 2024, an increase from 41,210 in 2023. Consequently, the surge in insulin resistance, linked with numerous liver issues and diabetes, is catalyzing the growth of the non-alcoholic steatohepatitis treatment market.

Request Your Free Non-Alcoholic Steatohepatitis Treatment Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp

Who Are the Influential Players Reshaping the Non-Alcoholic Steatohepatitis Treatment Market Landscape?

Major companies operating in the non-alcoholic steatohepatitis treatment market are:

• AstraZeneca PLC_x000D_

• Galmed Pharmaceuticals Ltd._x000D_

• Genfit S.A._x000D_

• Zydus Cadila Healthcare Limited_x000D_

• Bristol-Myers Squibb Company_x000D_

What New and Evolving Trends Are Having a Lasting Impact on the Non-Alcoholic Steatohepatitis Treatment Market?

The trend of non-alcoholic steatohepatitis (NASH) drug development is becoming increasingly prevalent in the non-alcoholic steatohepatitis treatment market. Numerous enterprises are focusing their resources on inventing novel drugs for liver conditions, with an emphasis on minimising the drugs’ side effects. For example, in May 2022, the American pharmaceutical and biotechnology business, Pfizer Inc., was awarded a fast-track designation grant by the U.S. Food and Drug Administration (FDA) to expedite the progression of the NASH drug, ervogastat and clesacostat. Pfizer’s investigational combination therapy, ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi), designed to treat NASH with liver fibrosis, falls under this Fast Track process.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report

What Are the Core Segments of the Non-Alcoholic Steatohepatitis Treatment Market, and How Do They Contribute to Growth?

The non-alcoholic steatohepatitis treatment market covered in this report is segmented –

1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types

2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures

3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users

Subsegments:

1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.

2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH

3) By Elafibranor: Elafibranor-Based Treatments

4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations

5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid

6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies

Which Geographic Locations Are Critical to the Growth of the Non-Alcoholic Steatohepatitis Treatment Market?

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Defining Aspects of the Non-Alcoholic Steatohepatitis Treatment Market Landscape?

The non-alcoholic steatohepatitis treatment refers to a treatment used in steatohepatitis by maintaining a healthy diet, control of blood sugar, loss of body weight and fat. It is a treatment type for liver disease in which people who drink little, or no alcohol develop fatty livers. This causes liver cell destruction and inflammation, which can lead to cirrhosis.

Browse Through More Similar Reports By The Business Research Company:

Protein Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/protein-supplements-global-market-report

Nutritional Analysis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/nutritional-analysis-global-market-report

Probiotics Dietary Supplements Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/probiotics-dietary-supplements-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: